-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chimeric antigen receptor T cell (CAR-T) therapy, as a disruptive innovative therapy, is booming in China
.
On June 22, 2021, Yikaida® (Akilunza injection) was formally approved by the National Medical Products Administration (NMPA), becoming China’s first CAR-T therapy drug targeting CD19 for the treatment of previously accepted drugs Adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) after second-line or above systemic treatment have brought new treatment options for R/R LBCL
.
At present, it has been approved in 38 countries around the world, and has accumulated nearly 5,000 patient experience
.
In order to promote the development of China's CAR-T field, build China's CAR-T star treatment center, and cooperate with international and domestic diagnosis and treatment
.
"CCSC (China CAR-T Star Center)-Kylinhui International Connection" continues! October 20, 2021-The new phase of Kylin Club International Connection was successfully held in Shanghai
.
This conference is fortunate to invite Professor Liang Aibin from Tongji Hospital Affiliated to Tongji University, Professor Robin Sanderson from King's College Hospital, Professor Li Ping from Tongji Hospital Affiliated to Tongji University, Doctor Ye Shiguang from Tongji Hospital Affiliated to Tongji University, and many top domestic experts as speakers and discussions Guests, focusing on cutting-edge topics in the field of CAR-T cell therapy, conducted in-depth discussions and exchanges on Fosun Kate’s CAR-T cell therapy drug Yikaida® (Akilunza injection)
.
Below, I will take you to review the wonderful links of this conference.
I hope that this conference can expand clinicians' understanding of the clinical efficacy of Akirensai injection and further improve the clinical benefits of patients
.
In this session, Dr.
Ye Shiguang from Tongji Hospital Affiliated to Tongji University shared the achievements of Tongji Hospital in CAR-T
.
Dr.
Ye Shiguang first introduced the team leader Professor Liang Aibin and Professor Li Ping of Tongji Hospital Affiliated to Tongji University, and then made a systematic and clear explanation of the team's clinical research and treatment experience in CAR-T
.
In terms of clinical research, Dr.
Ye Shiguang introduced a study using CD19 CAR-T to treat relapsed and refractory B-cell malignancies.
One of the patients has been "clinically cured"
.
There are also a number of other studies using CAR-T to treat patients with relapsed and refractory lymphoma or leukemia that have achieved striking results
.
In addition, Tongji Hospital has made considerable progress in the development of guidelines for CAR-T cell therapy and the exploration of detection technologies
.
In terms of treatment experience, Tongji Hospital first focuses on the toxicity management of CAR-T cell therapy, especially the management of cytokine release syndrome (CRS) and hepatitis B virus (HBV) reactivation; the second is CD19 The rescue treatment of patients with failed CAR-T treatment was explored, and drugs such as CD19 PD-1, CD28 CAR-T, and CD20 CAR-T were tried; the third is to study overcoming tumor antigen escape, using CD20/CD19 Bi CAR- T for treatment
.
Foreign CAR-T research and exploration of reality continue to break into this link.
Professor Robin Sanderson from King's College Hospital gave a speech entitled "Yescarta for Relapsed DLBCL: Real world experience and lessons learnt"
.
Professor Robin Sanderson gave a brief description of the start of CAR-T treatment in the UK, compared the basic characteristics of the four CAR-T treatment drugs currently on the market, and introduced in detail the CAR-T treatment of King's College Hospital.
Research results
.
In King's College Hospital, after 13.
1 months of follow-up, the median survival (OS) of patients with relapsed and refractory diffuse large B-cell lymphoma DLBCL did not reach, and the main toxicity after CAR-T treatment—the incidence of neurotoxicity has been Lower than ZUMA-1 research
.
Therefore, Professor Robin Sanderson believes that Akirensai injection is suitable for the third-line treatment of lymphoma patients
.
He also shared 2 cases of DLBCL patients, all of whom achieved partial metabolic remission (PMR) at 1 month after CAR-T treatment.
The imaging examinations at 3 and 6 months were also confirmed as complete metabolic remission (CMR).
.
In addition, Professor Robin Sanderson also elaborated on his understanding of patients' COVID-19 infection, the correlation between CAR-T treatment and CRS, neutrophil count, and the mechanism of recurrence
.
Finally, Professor Robin Sanderson concluded that CAR-T therapy has a real effect on patients who are refractory to chemotherapy.
The toxicity of the current treatment has also been well managed, and it is a very exciting new therapy
.
International exchanges to create a new future for CAR-T therapy.
Participating experts discussed the sharing of Professor Robin Sanderson
.
Professor Liang Aibin introduced the current status of CAR-T treatment for only 40%-50% of refractory patients in China.
He affirmed the control of infection by the team of Professor Robin Sanderson.
He believes that there are more bacterial infections in the clinic and viruses.
Secondly, fungus again, so the use of hormones is more restrained
.
Later, Professor Liang Aibin also asked questions about the relationship between CAR-T treatment and transplantation
.
Professor Robin Sanderson said that in the observation of 380 patients, he found that the use of hormones does not affect PFS and EFS, so he is more open to the use of hormones; regarding the relationship between CAR-T and transplantation, before CAR-T treatment, For patients who have achieved partial remission in pre-treatment, he would recommend CAR-T therapy instead of transplantation.
After CAR-T therapy, most of them are observed first, and then measures are taken for patients with disease progression
.
Professor Robin Sanderson also expressed his appreciation for Tongji Hospital's current research on CD70 CAR-T and the combined use of CD19 and CD20 drugs.
He is currently exploring the combined use of CAR-T therapy with other drugs, such as PD-1
.
Summary At the end, Professor Liang Aibin made a summary of the meeting
.
I would like to express my gratitude to Professor Robin Sanderson for sharing his experience.
I hope that we can continue to communicate and cooperate in the future.
I also believe that as the research on CAR-T therapy continues to deepen, the CAR-T treatment plan will be more perfect and ultimately change the field of lymphoma and hematology.
The treatment ecology can achieve long-term and good survival benefits for patients! Poke "read the original text", we make progress together
.
On June 22, 2021, Yikaida® (Akilunza injection) was formally approved by the National Medical Products Administration (NMPA), becoming China’s first CAR-T therapy drug targeting CD19 for the treatment of previously accepted drugs Adult patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) after second-line or above systemic treatment have brought new treatment options for R/R LBCL
.
At present, it has been approved in 38 countries around the world, and has accumulated nearly 5,000 patient experience
.
In order to promote the development of China's CAR-T field, build China's CAR-T star treatment center, and cooperate with international and domestic diagnosis and treatment
.
"CCSC (China CAR-T Star Center)-Kylinhui International Connection" continues! October 20, 2021-The new phase of Kylin Club International Connection was successfully held in Shanghai
.
This conference is fortunate to invite Professor Liang Aibin from Tongji Hospital Affiliated to Tongji University, Professor Robin Sanderson from King's College Hospital, Professor Li Ping from Tongji Hospital Affiliated to Tongji University, Doctor Ye Shiguang from Tongji Hospital Affiliated to Tongji University, and many top domestic experts as speakers and discussions Guests, focusing on cutting-edge topics in the field of CAR-T cell therapy, conducted in-depth discussions and exchanges on Fosun Kate’s CAR-T cell therapy drug Yikaida® (Akilunza injection)
.
Below, I will take you to review the wonderful links of this conference.
I hope that this conference can expand clinicians' understanding of the clinical efficacy of Akirensai injection and further improve the clinical benefits of patients
.
In this session, Dr.
Ye Shiguang from Tongji Hospital Affiliated to Tongji University shared the achievements of Tongji Hospital in CAR-T
.
Dr.
Ye Shiguang first introduced the team leader Professor Liang Aibin and Professor Li Ping of Tongji Hospital Affiliated to Tongji University, and then made a systematic and clear explanation of the team's clinical research and treatment experience in CAR-T
.
In terms of clinical research, Dr.
Ye Shiguang introduced a study using CD19 CAR-T to treat relapsed and refractory B-cell malignancies.
One of the patients has been "clinically cured"
.
There are also a number of other studies using CAR-T to treat patients with relapsed and refractory lymphoma or leukemia that have achieved striking results
.
In addition, Tongji Hospital has made considerable progress in the development of guidelines for CAR-T cell therapy and the exploration of detection technologies
.
In terms of treatment experience, Tongji Hospital first focuses on the toxicity management of CAR-T cell therapy, especially the management of cytokine release syndrome (CRS) and hepatitis B virus (HBV) reactivation; the second is CD19 The rescue treatment of patients with failed CAR-T treatment was explored, and drugs such as CD19 PD-1, CD28 CAR-T, and CD20 CAR-T were tried; the third is to study overcoming tumor antigen escape, using CD20/CD19 Bi CAR- T for treatment
.
Foreign CAR-T research and exploration of reality continue to break into this link.
Professor Robin Sanderson from King's College Hospital gave a speech entitled "Yescarta for Relapsed DLBCL: Real world experience and lessons learnt"
.
Professor Robin Sanderson gave a brief description of the start of CAR-T treatment in the UK, compared the basic characteristics of the four CAR-T treatment drugs currently on the market, and introduced in detail the CAR-T treatment of King's College Hospital.
Research results
.
In King's College Hospital, after 13.
1 months of follow-up, the median survival (OS) of patients with relapsed and refractory diffuse large B-cell lymphoma DLBCL did not reach, and the main toxicity after CAR-T treatment—the incidence of neurotoxicity has been Lower than ZUMA-1 research
.
Therefore, Professor Robin Sanderson believes that Akirensai injection is suitable for the third-line treatment of lymphoma patients
.
He also shared 2 cases of DLBCL patients, all of whom achieved partial metabolic remission (PMR) at 1 month after CAR-T treatment.
The imaging examinations at 3 and 6 months were also confirmed as complete metabolic remission (CMR).
.
In addition, Professor Robin Sanderson also elaborated on his understanding of patients' COVID-19 infection, the correlation between CAR-T treatment and CRS, neutrophil count, and the mechanism of recurrence
.
Finally, Professor Robin Sanderson concluded that CAR-T therapy has a real effect on patients who are refractory to chemotherapy.
The toxicity of the current treatment has also been well managed, and it is a very exciting new therapy
.
International exchanges to create a new future for CAR-T therapy.
Participating experts discussed the sharing of Professor Robin Sanderson
.
Professor Liang Aibin introduced the current status of CAR-T treatment for only 40%-50% of refractory patients in China.
He affirmed the control of infection by the team of Professor Robin Sanderson.
He believes that there are more bacterial infections in the clinic and viruses.
Secondly, fungus again, so the use of hormones is more restrained
.
Later, Professor Liang Aibin also asked questions about the relationship between CAR-T treatment and transplantation
.
Professor Robin Sanderson said that in the observation of 380 patients, he found that the use of hormones does not affect PFS and EFS, so he is more open to the use of hormones; regarding the relationship between CAR-T and transplantation, before CAR-T treatment, For patients who have achieved partial remission in pre-treatment, he would recommend CAR-T therapy instead of transplantation.
After CAR-T therapy, most of them are observed first, and then measures are taken for patients with disease progression
.
Professor Robin Sanderson also expressed his appreciation for Tongji Hospital's current research on CD70 CAR-T and the combined use of CD19 and CD20 drugs.
He is currently exploring the combined use of CAR-T therapy with other drugs, such as PD-1
.
Summary At the end, Professor Liang Aibin made a summary of the meeting
.
I would like to express my gratitude to Professor Robin Sanderson for sharing his experience.
I hope that we can continue to communicate and cooperate in the future.
I also believe that as the research on CAR-T therapy continues to deepen, the CAR-T treatment plan will be more perfect and ultimately change the field of lymphoma and hematology.
The treatment ecology can achieve long-term and good survival benefits for patients! Poke "read the original text", we make progress together
